HOME >> BIOLOGY >> NEWS
Clemson Researchers Turn Crabshells Into New Product Lines

McCLELLANVILLE D Clemson University researchers have developed a new process to turn crab shells into natural marketable products. Food and packaging scientists Ronald L. Thomas and Robert F. Testin at Clemson are working with W.E. (Eddie) Gordon, owner of the South Carolina Crab Company in McClellanville, to process crab shells into promising new product lines.

"Ninety percent of the shellfish is discarded in traditional seafood processing operations around the world," Thomas said. "We've developed a process to completely eliminate that and use 100 percent of the product."

The process is a closed-loop system that extracts the remainder of food-grade meat from the shells, then reduces the shells to their primary materials D chitin and calcium D with no discharge into the environment. The chitin can then be converted into chitosan and glucosamine, products that are in high demand by the food supplement industry, the medical profession, manufacturing and agriculture.

The food supplement, or nutraceutical industry, sells glucosamine as a treatment for chronic arthritis and chitosan as a natural fiber for reducing cholesterol and absorbing fat. Physicians use chitosan film as an "artificial skin" to treat burns and severe wounds because of its antimicrobial properties. Manufacturers use chitosan as a natural polymer to remove heavy metals from industrial waste water. Agriculture uses chitosan as a feed supplement for hogs and as a seed coating. The cosmetic industry uses it in shampoos and face creams.

"Chitin is the second most abundant natural polymer in the world after cellulose," Thomas said. "We're just beginning to explore all its possible applications."

Gordon's South Carolina Crab Company is developing a prototype system to process food-grade chitin, calcium and crab meat from the shells. The system is currently undergoing testing and refinements, with the possibility of commercial application t
'"/>

Contact: Ron Thomas
rthms@clemson.edu
864-656-5697
Clemson University
18-Dec-1998


Page: 1 2

Related biology news :

1. Clemson University spin-off uses corn to make plastics, provide cleaner air
2. Clemson researcher places hope on pushy photons
3. Clemson researcher receives Komen grant
4. Clemson University researcher reaches for the stars to prevent osteoporosis
5. Clemson launches S.C. DNA Learning Center
6. Clemson dedicates biotech research complex
7. Breakthrough Clemson research appears in Science
8. Clemson researcher takes part in breakthrough research on insects
9. Clemson researchers find bacteria fighter that does not promote bacterial resistance
10. Clemson researchers identify mental retardation gene
11. Clemson researchers create biosensors to protect nations food and water supplies

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Clemson Researchers Turn Crabshells Into New Product Lines

(Date:10/22/2014)... Medicine® scientists helps explain how bipolar disorder affects the ... therapies to treat the mental illness. , Scientists ... method recognized with the 2014 Nobel Prize in ... from mice with bipolar-like behaviors. In the synapses (where ... structures with concentrated levels of ANK3 -- the gene ...
(Date:10/22/2014)... , Oct. 20, 2014  Leading identity analyst firm ... half of the world,s population will have a chip-based ... Europe . Asia , ... market accounting for more than 60% of all National ... Acuity,s report  -- "The Global National eID ...
(Date:10/19/2014)... in India over the last 30 years contributed ... growth during that time, according to a new ... Change ., "Energy access is fundamental to development: ... including education, communication, and health," says IIASA researcher ... increased energy access is widely agreed to be ...
Breaking Biology News(10 mins):Bipolar disorder discovery at the nano level 2Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Improved electricity access has little impact on climate change 2
(Date:10/25/2014)... , October 24, 2014 ... Corporation (NASDAQ: CYTR ), Vertex Pharmaceuticals Inc. ... ALXN ), Peregrine Pharmaceuticals Inc. (NASDAQ: ... research on these five companies can be accessed at: ... Thursday, October 23, 2014, ended on a positive note ...
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis ... specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, today ... to acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., ... for the treatment of diabetic gastroparesis and other GI ... successful Phase 2 trial of relamorelin for the treatment ...
(Date:10/22/2014)... WriteResult, LLC – a premier provider of ... a team of researchers from Yale University’s School of ... to provide electronic questionnaire data collection through use of ... in May, aims to evaluate the impact of a ... and participation in urban agriculture to impact their consumption ...
(Date:10/22/2014)... ROCKVILLE, Md. , Oct. 22, 2014   ... company developing novel pathogen-specific therapies for serious infections and ... Office has issued a Notice of Allowance for a ... product in its C. difficile program, SYN-004. This ... to SYN-004 in the U.S. and adds to the ...
Breaking Biology Technology:Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
Cached News: